Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia (AML) six years ago. During this period of partial remission, Rose researched investigational drugs to be prepared in the event of a relapse. Her husband died February 12, 2021 with a rare and unexplained occurrence of liver cancer possibly unrelated to AML.

    Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
    source: shutterstock.com

    Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma

    Shanghai's Junshi Biosciences Co. (The Company) recently announced in Biospace, that its product, toripalimab (TUOYI®), combined with bevacizumab as a first-line therapy for hepatocellular carcinoma (HCC), met its endpoints in a…

    Continue Reading Toripalimab Combined with Bevacizumab Meets Primary Endpoint for Advanced Hepatocellular Carcinoma
    Long COVID: What Have We Learned?
    source: shutterstock.com

    Long COVID: What Have We Learned?

    Individuals who appear to have Long COVID may exhibit a variety of symptoms lasting weeks or even years. The latest estimates are that about 10-20% of people infected with SARS-CoV-2…

    Continue Reading Long COVID: What Have We Learned?
    Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
    source: shutterstock.com

    Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model

    A team of scientists from Japan appear to have pioneered a method for reversing synapse damage in an Alzheimer's disease mouse model. Although encouraging, the theory must be tested in…

    Continue Reading Japanese Scientists Reversed Signs of Alzheimer’s by Restoring Synapse Function in Mouse Model
    FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease
    source: shutterstock.com

    FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease

    The idiom ‘third time’s a charm’ may have some significance in this instance. The panel that advises the FDA just voted unanimously in favor of Eli Lilly’s experimental drug, donanemab.…

    Continue Reading FDA’s Panel of Experts Vote 11-0 in Favor of Donanemab to Treat Alzheimer’s Disease
    Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
    source: shutterstock.com

    Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens

    Professor Michael Goran was referring to research data that was presented at the annual 2023 conference of the Hepatology, Gastroenterology, and Nutrition Society of North America when he stressed that…

    Continue Reading Higher Sugar Intake Boosts Risk of Liver Fibrosis in Latino Teens
    Farxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes
    source: shutterstock.com

    Farxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes

    Ruud Dobber, executive VP of biopharmaceuticals at AstraZeneca was quoted in a press release dated saying that type 2 diabetes is on the rise in adolescents and younger children with…

    Continue Reading Farxiga® has been FDA Approved to Treat Children and Adolescents in the U.S. for Type 2 Diabetes
    Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
    source: shutterstock.com

    Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD

    Pfizer has recently paused its Phase III clinical trial that has been assessing the Duchenne muscular dystrophy candidate fordadistrogene movaparvovec. The Phase II DAYLIGHT trial (NCT05429372), enrolled ten boys ages…

    Continue Reading Pfizer Acknowledges the Death of a Young Boy Who Died One Year After Participating in its Phase II Clinical Trial to Treat DMD
    Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
    source: pixabay.com

    Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®

    This week Neurocrine Biosciences announced the results of its KINECT®-4 Phase 3 study of INGREZZA® capsules. Results of the trial were published in the Journal of Clinical Psychopharmacology. A long-term…

    Continue Reading Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
    Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
    shutterstock.com

    Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis

    Cartesian Therapeutics, Inc., a biotechnology company, recently announced that the FDA has awarded the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, Descartes-08, to treat myasthenia gravis (MG).…

    Continue Reading Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
    Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
    kkolosov / Pixabay

    Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients

    BioSpace recently published a press release discussing the interim results highlighting a Coya Therapeutics’ study. The study evaluates the safety, tolerability, and biological activity of LD IL-2 in 38 patients…

    Continue Reading Encouraging Results from a Phase 2 Study of IL-2 to Treat Alzheimer’s Patients
    Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
    source: shutterstock.com

    Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy

    Jianmin Fang, M.D. the CEO of the biotechnology company RemeGen, recently announced in PRNewswire that the company is continuing its significant progress in its research of Telitacicept (RC18) to treat…

    Continue Reading Enrollment Completed in Clinical Trials for Primary Sjögren’s Syndrome and IgA Nephropathy
    Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone
    source: pixabay.com

    Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone

    People who have bipolar depression face a 50% lifetime risk of attempting suicide and a 20% risk of death from suicide. Over seven million people in the U.S. are struggling…

    Continue Reading Suicidal Bipolar Depression: Clinical Trial Results of NRX-101 Found Superior Safety and Similar Efficacy Compared to Lurasidone
    New FDA Regulation on Laboratory Developed Tests Draws Objections from Healthcare Groups
    source: shutterstock.com

    New FDA Regulation on Laboratory Developed Tests Draws Objections from Healthcare Groups

    As reported in Biopharma Dive, the FDA’s decision to strengthen its authority involving laboratory developed tests (LDTs) has drawn considerable objections from various healthcare groups. However, the Agency has held…

    Continue Reading New FDA Regulation on Laboratory Developed Tests Draws Objections from Healthcare Groups